Navigation Links
Certain Painkillers Appear to Boost Odds for Heart Attack
Date:1/12/2011

By Steven Reinberg
HealthDay Reporter

TUESDAY, Jan. 11 (HealthDay News) -- Common painkillers taken to treat inflammation, such as Celebrex and Advil, can raise the risk of heart attack, stroke or death, a review of existing research suggests.

Swiss researchers analyzed the results of 31 trials involving seven non-steroidal anti-inflammatory drugs (NSAIDs), as these medications are called, and concluded that cardiovascular risk needs to be considered before prescribing any of them.

"NSAIDs are widely used worldwide for treating pain and inflammation," said Dr. Gregg Fonarow, American Heart Association spokesman and professor of cardiology at the University of California, Los Angeles.

"A number of studies have shown that many of these agents are associated with increased risk of cardiovascular events, particularly when used at higher doses and for longer periods of time, but uncertainty remains as to the magnitude of the risk and how the cardiovascular risk may vary among different NSAIDs," said Fonarow, who was not involved in the study.

All the NSAIDs studied increased the risk of cardiovascular events, but the magnitude of risk is small in absolute terms -- approximately one cardiovascular event per 100 patient-years of follow-up, Fonarow noted.

"In many patients the benefits provided by these agents may outweigh the risk, and other steps can be taken to reduce the patient's cardiovascular risk," he said.

The report is published in the Jan. 11 online edition of the BMJ.

In 2004, the drug Vioxx (rofecoxib), which belonged to a class of NSAIDs called COX-2 inhibitors, was pulled from the market because of its link to an increased risk of heart attack.

To explore the connection between NSAIDs and heart problems, a team led by Dr. Peter Juni, from the Institute of Social and Preventive Medicine at the University of Bern, reviewed 31 trials that included 116,429 patients. This method of reviewing trial findings to uncover a pattern is called a meta-analysis.

The painkillers the patients were taking included naproxen (Aleve), ibuprofen (Advil, Motrin), diclofenac (Voltaren, Cataflam), celecoxib (Celebrex), etoricoxib (Arcoxia), rofecoxib (Vioxx), lumiracoxib (Prexige) or placebo.

Overall, the number of heart events among patients taking NSAIDs was low, the researchers found. In 29 trials, 554 heart attacks occurred. In 26 trials, 377 strokes were reported, and in 28 trials, 676 people died.

Compared with patients taking placebo, those taking rofecoxib and lumiracoxib had twice the risk of heart attack, and those taking ibuprofen had more than three times the risk of stroke. The highest risks for cardiac death were associated with etoricoxib and diclofenac, where the risk was around four times greater than for placebo, the researchers found.

Naproxen appeared to be the least harmful medication, they noted.

"Our study provides the best available evidence on the safety of this class of drugs," the researchers wrote. "Although uncertainty remains, little evidence exists to suggest that any of the investigated drugs are safe in cardiovascular terms. Cardiovascular risk needs to be taken into account when prescribing any non-steroidal anti-inflammatory drug," they concluded.

Commenting on the study, Dr. Eric J. Topol, director of the Scripps Translational Science Institute and one of the experts who uncovered the risks associated with Vioxx, said a meta-analysis can leave many questions unanswered but is of value nonetheless.

"Pooling large data sets like this winds up with ambiguity as it homogenizes differences in patient population characteristics, dose of drugs, how endpoints were ascertained and when, etc.," he said. "I am not sure if the conclusions reflect or agree with other meta-analysis results," Topol noted.

"Despite the limitations, this study has made many excellent contributions on the NSAID issue, so we need to factor these into the mix," Topol said.

More information

For more information on NSAIDs, visit the U.S. Food and Drug Administration.

SOURCES: Eric J. Topol, M.D., director, Scripps Translational Science Institute, La Jolla, Calif.; Gregg Fonarow, M.D., American Heart Association spokesman, and professor, cardiology, University of California, Los Angeles; Jan. 11, 2011, BMJ, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
2. Certain pain medications do not appear to be associated with skin cancer risk
3. AGA offers new recommendations for CRC surveillance for certain patients with IBD
4. Smoking significantly increases risk of aneurysm in people with certain genes
5. American Stroke Association Late-Breaking Science Report: Surgery, Stenting to Open Blocked Neck Arteries Similar in Safety, Efficacy, But Show Differences in Stroke, Heart Attack and Death Rates at Certain Ages
6. Certain Bone Drugs May Lower Breast Cancer Risk
7. Football Injuries More Likely on Certain Artificial Turf
8. Plavix Can Help Cut Death Risk in Certain Heart Patients
9. The Worst Is Over, but the Road to Growth Is Uncertain - The 17th Annual CFO Rising Conference & Exhibition
10. Perhaps a longer lifespan, certainly a longer health span
11. One in Five Parents Would Spank in Certain Settings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Certain Painkillers Appear to Boost Odds for Heart Attack
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 ... , and OptiMed Specialty Pharmacy of Kalamazoo, ... offer a strategic hub service that expedites and streamlines ... personal spirometer, Spiro PD 2.0, and wellness management services.  ... is a medical device used to measure lung function ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
(Date:9/9/2017)... 8, 2017 ... Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th .The ... free MRI brain scans to the public.Where:  BTF,s ... at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the ...
Breaking Medicine Technology: